Avalo Therapeutics Inc (AVTX)
11.94
+0.19
(+1.62%)
USD |
NASDAQ |
May 31, 16:00
11.50
-0.44
(-3.69%)
After-Hours: 20:00
Avalo Therapeutics Research and Development Expense (TTM): 9.89M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.89M |
| December 31, 2023 | 13.78M |
| September 30, 2023 | 18.09M |
| June 30, 2023 | 23.88M |
| March 31, 2023 | 27.73M |
| December 31, 2022 | 31.31M |
| September 30, 2022 | 36.65M |
| June 30, 2022 | 40.16M |
| March 31, 2022 | 44.21M |
| December 31, 2021 | 59.84M |
| September 30, 2021 | 60.96M |
| June 30, 2021 | 59.28M |
| March 31, 2021 | 52.63M |
| December 31, 2020 | 32.19M |
| September 30, 2020 | 22.46M |
| June 30, 2020 | 15.34M |
| March 31, 2020 | 13.13M |
| December 31, 2019 | 11.76M |
| September 30, 2019 | 10.86M |
| Date | Value |
|---|---|
| June 30, 2019 | 10.17M |
| March 31, 2019 | 7.538M |
| December 31, 2018 | 5.787M |
| September 30, 2018 | 5.742M |
| June 30, 2018 | 5.658M |
| March 31, 2018 | 5.069M |
| December 31, 2017 | 4.373M |
| September 30, 2017 | 3.184M |
| June 30, 2017 | 6.802M |
| March 31, 2017 | 8.810M |
| December 31, 2016 | 10.15M |
| September 30, 2016 | 11.13M |
| June 30, 2016 | 7.784M |
| March 31, 2016 | 7.157M |
| December 31, 2015 | 6.587M |
| September 30, 2015 | 7.095M |
| June 30, 2015 | 10.23M |
| March 31, 2015 | 11.21M |
| December 31, 2014 | 12.24M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
9.89M
Minimum
Mar 2024
60.96M
Maximum
Sep 2021
29.72M
Average
25.81M
Median
Research and Development Expense (TTM) Benchmarks
| Imunon Inc | 11.96M |
| iBio Inc | 6.401M |
| Kodiak Sciences Inc | 179.71M |
| Petros Pharmaceuticals Inc | 3.646M |
| Ocugen Inc | 36.84M |